Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15718994 | 1.00 | CXCR4 (0.54) | CXCR4JAK2JAK1TYK2JAK3 | |
| SCHEMBL17182961 | 1.00 | CXCR4 (0.54) | CXCR4JAK2JAK1TYK2JAK3 | |
| SCHEMBL31305922 | 0.94 | CXCR4 (0.59) | CXCR4JAK2JAK1TYK2JAK3 | |
| SCHEMBL27091329 | 0.87 | CHRM2 (0.53) | CXCR4KMT2AALDH1A1CHRM2DPP7 | |
| SCHEMBL29336471 | 0.86 | HTT (0.62) | CXCR4KMT2AALDH1A1CHRM2DPP7 | |
| SCHEMBL353907 | 0.83 | CXCR4 (0.53) | CXCR4KMT2AALDH1A1CHRM2DPP7 | |
| SCHEMBL24291613 | 0.81 | ALDH1A1 (0.62) | KMT2AALDH1A1MEN1SMN1; SMN2NPC1 | |
| SCHEMBL22023702 | 0.80 | HRH3 (0.52) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11941096 | 0.78 | CXCR4 (0.47) | CXCR4JAK2JAK1TYK2JAK3 | |
| SCHEMBL7330860 | 0.78 | CXCR4 (0.61) | CXCR4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570143-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2020-02-25 | — | — | US | disclosed |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-07 | — | — | US | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| EP-2920181-B1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIV HEALTH NETWORK (CA) | 2019-01-09 | — | — | EP | disclosed |
| US-10106545-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-23 | — | — | US | disclosed |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9573954-B2 | Pyrazolopyrimidine compounds | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-21 | — | — | US | disclosed |
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2015-10-22 | — | — | US | disclosed |
| EP-2920181-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | University Health Network (UHN) (CA) | 2015-09-23 | — | — | EP | disclosed |
| US-8993470-B2 | Catalysts for the alkyne metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-03-31 | — | — | US | disclosed |
| WO-2014075168-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | UNIVERSITY HEALTH NETWORK (CA) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299203-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | CXCR4 2873/4885JAK2 143/4885JAK1 108/4885 |
| US-10570143-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | CXCR4 2873/4885JAK2 143/4885JAK1 108/4885 |
| US-10106545-B2 | Pyrazolopyrimidine compounds | CYP3A5, CYP3A7, DPYD | CXCR4 3067/4885JAK2 186/4885JAK1 275/4885 |
| US-20170217966-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | CXCR4 3067/4885JAK2 186/4885JAK1 275/4885 |
| US-20190040074-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS | CYP3A5, CYP3A7, DPYD | CXCR4 3067/4885JAK2 186/4885JAK1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.